Regular examination of the lungs using magnetic resonance imaging (MRI) can detect how lung disease develops in children with cystic fibrosis.
A clinical trial has shown that a triple combination therapy consisting of three known compounds is both safe and effective in cystic fibrosis patients with relatively rare disease-causing genetic defects.
Researchers of DZL analyzed lung collagen degradation and found a way to predict the course of an antibody therapy with omalizumab.
The annual ERS International Congress will be held in 2021 from September 5-8 as an online congress. Respiratory experts worldwide will connect online to present and discuss the latest scientific and clinical advances in respiratory...
Children can also be infected with the novel coronavirus SARS-CoV-2, but have a substantially lower risk for developing severe COVID-19 disease compared to adults.
COVID-19 disease severity is determined by the individual patient’s immune response. The precise mechanisms taking place inside the lungs and blood during the early phase of the disease remain unclear.
A collaboration of multiple research institutions with researchers of the DZL site Munich involved reveals the cellular activation states of SARS-CoV-2 reactive T cells in the lung and blood. The study was published in Nature...
The Fraunhofer Institute for Toxicology and Experimental Medicine is involved in two BMBF projects investigating new drugs against COVID-19.
Dr. Gabriele Schramm, a scientist at the DZL site ARCN, has discovered that basophilic granulocytes are important for rapid and efficient recovery after a heart attack.
Researchers from the DZL's BREATH site in Hanover are the first to clearly demonstrate the existence of lipofibroblasts in the human lung using electron microscopy.
Dr. Carmela Morrone from the DZL Site Munich was awarded the Dissertation Award 2021 of the ,Deutsche Lungenstiftung e.V.´
The DZL scientist Prof. Thomas Bahmer from Kiel received this year’s Clinical Research Award of the German Respiratory Society (DGP).
